Press releases
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
- Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
More ▼
Key statistics
As of last trade Sarepta Therapeutics Inc (AB3A:FRA) traded at 117.10, -13.74% below its 52-week high of 135.75, set on May 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 117.10 |
---|---|
High | 117.10 |
Low | 117.10 |
Bid | 116.85 |
Offer | 117.95 |
Previous close | 118.10 |
Average volume | 279.78 |
---|---|
Shares outstanding | 94.52m |
Free float | 89.83m |
P/E (TTM) | 1,595.71 |
Market cap | 12.02bn USD |
EPS (TTM) | 0.0797 USD |
Data delayed at least 15 minutes, as of May 24 2024 07:03 BST.
More ▼